Kristen Upham
Family · Peabody, MANPI 1235489121
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,471 and has fallen 92.1% since, to $117 in 2025. Among family clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cequr Corporation$781
- Novo Nordisk$366
- Amgen$316
- Lilly USA, LLC$293
- AstraZeneca$280
- Xeris Pharmaceuticals, Inc.$255
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,135100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cequr Corporation | 4 | $781 |
| Novo Nordisk | 20 | $366 |
| Amgen | 16 | $316 |
| Lilly USA, LLC | 14 | $293 |
| AstraZeneca | 15 | $280 |
| Xeris Pharmaceuticals, Inc. | 12 | $255 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $187 |
| Sanofi-aventis U.S. LLC | 4 | $172 |
| Boehringer Ingelheim | 9 | $170 |
| Pfizer | 8 | $158 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Idorsia Pharmaceuticals US Inc | 4 | $90 |
| Ultragenyx Pharmaceutical Inc. | 4 | $88 |
| Bausch Health US, LLC | 4 | $83 |
| Novartis | 5 | $78 |
| Dexcom, Inc. | 2 | $76 |
| Mannkind Corporation | 4 | $73 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| Genentech USA, Inc. | 3 | $50 |
| Exact Sciences | 2 | $46 |
| GSK | 2 | $45 |
| Corcept Therapeutics | 2 | $44 |
| Zealand Pharma US, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Medtronic | 2 | $37 |
| Bayer | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Averitas Pharma Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Abbott | 1 | $24 |
| Johnson & Johnson | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$781
- TOUJEO$101
How this compares
$4,135 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 23 | $396 |
| Levothyroxine Sodium | 17 | $334 |
| Atorvastatin Calcium | 12 | $277 |
| Rosuvastatin Calcium | 12 | $204 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $196 |
| Lorazepam | 28 | $110 |
| Doxycycline Hyclate | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Other family in Peabody
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
- Leslie StefanowiczDartmouth$56K
- Marissa CasilloFoxborough$31K
- Rochelle NazarianDanvers$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.